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Background. Human immunodeficiency virus (HIV) takes advantage of multiple host proteins to support its
own replication. The gene ZNRD1 (zinc ribbon domain–containing 1) has been identified as encoding a potential
host factor that influenced disease progression in HIV-positive individuals in a genomewide association study and
also significantly affected HIV replication in a large-scale in vitro short interfering RNA (siRNA) screen. Genes
and polymorphisms identified by large-scale analysis need to be followed up by means of functional assays and
resequencing efforts to more precisely map causal genes.
Methods. Genotyping and ZNRD1 gene resequencing for 208 HIV-positive subjects (119 who experienced
long-term nonprogression [LTNP] and 89 who experienced normal disease progression) was done by either TaqMan
genotyping assays or direct sequencing. Genetic association analysis was performed with the SNPassoc package
and Haploview software. siRNA and short hairpin RNA (shRNA) specifically targeting ZNRD1 were used to
transiently or stably down-regulate ZNRD1 expression in both lymphoid and nonlymphoid cells. Cells were infected
with X4 and R5 HIV strains, and efficiency of infection was assessed by reporter gene assay or p24 assay.
Results. Genetic association analysis found a strong statistically significant correlation with the LTNP phenotype
(single-nucleotide polymorphism rs1048412; ), independently of HLA-A10 influence. siRNA-based func-Pp .0004
tional analysis showed that ZNRD1 down-regulation by siRNA or shRNA impaired HIV-1 replication at the
transcription level in both lymphoid and nonlymphoid cells.
Conclusion. Genetic association analysis unequivocally identified ZNRD1 as an independent marker of LTNP
to AIDS. Moreover, in vitro experiments pointed to viral transcription as the inhibited step. Thus, our data strongly
suggest that ZNRD1 is a host cellular factor that influences HIV-1 replication and disease progression in HIV-
positive individuals.
Humans show remarkable variation in their vulnera-
bility to infection with human immunodeficiency virus
(HIV), especially with respect to clinical outcome after
infection [1]. The considerable heterogeneity in the ep-
idemic is at least partially determined by variations in
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genes that influence virus replication and immunity [1].
The HIV type 1 (HIV-1) genome codes for only 15
proteins, requiring many cellular factors to complete
the virus replication cycle [2]. Thus, a large number of
host factors are likely to contribute to the variability of
HIV-related phenotypes, including genetic variants that
may be more or less advantageous for viral replication.
Recent advances in genomics and RNA interference
have led to the conduct of genomewide surveys to iden-
tify cellular genes that affect human disease [3–5] and
HIV replication [6–10]. The first genomewide associ-
ation analysis for determinants of HIV-1 host control
in humans identified a number of genomic regions as-
sociated with HIV load set point and/or disease pro-
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Table 1. Phenotype Data on Patients Included
in the Study
The table is available in its entirety in the online
version of Clinical Infectious Diseases
gression [7]. Among them, a locus on human chromosome 6,
close to the ZNRD1 (zinc ribbon domain–containing 1) and
RNF39 (ring finger protein 39) genes but also to HLA loci,
strongly correlated with HIV disease progression [7]. A ge-
nomewide functional screen also identified ZNRD1 among
1250 host factors required for HIV-1 replication [6]. Knowledge
of cellular factors and their interaction within the HIV-1 life
cycle are essential for a better understanding of virus replication
and disease pathogenesis, as well as for finding novel potential
therapeutic targets [11]. At least one identified cellular gene,
CCR5 (CC chemokine receptor 5), has been successfully ex-
ploited as a target for anti-HIV intervention [12, 13].
Despite their enormous power and interest, large-scale ge-
nomewide screens should be taken only as starting points. Ide-
ally, the identified genes should be analyzed in a physiologically
relevant cell system, and genetic associations should be vali-
dated in independent populations.
ZNRD1 encodes a protein consisting of 2 zinc ribbon do-
mains [14]. The C-terminal domain is well conserved in many
organisms as a transcription-associated motif [15]. Homology
searches identified ZNRD1 as encoding an RNA polymerase I
subunit [15]. By typing previously described and new poly-
morphisms in the ZNRD1 genomic region together with HLA-
A10, we unequivocally identify ZNRD1 as an independent
marker of long-term nonprogression (LTNP). In vitro exper-
iments showed that knockdown of ZNRD1 expression inhibited
HIV replication at transcription in both lymphoid and non-
lymphoid cells.
METHODS
Patients and samples. In total, 208 HIV-infected patients
(119 who experienced LTNP and 89 who experienced normal
disease progression) were included in the study (Table 1). Pro-
gressors from the HIV unit of the Hospital Universitari Ger-
mans Trias i Pujol were selected on the basis of having a CD4
cell count of !200 cells/mL with 10 years or fewer of reported
infection. Samples from LTNP patients were provided by the
HIV BioBank, using eligibility criteria modified from that re-
ported elsewhere [16]. Eligibility criteria were confirmed HIV
infection for 110 years, CD4 cell counts of 1500 cells/mL
throughout the course of infection, and viral loads of !5000
copies/mL without antiretroviral therapy.
Blood samples were processed in accordance with current
procedures. All patients who participated in the study provided
informed consent, and protocols were approved by the Sci-
entific Committee of Fundacio´ IrsiCaixa.
Genotyping of DNA samples. The entire coding sequence
of the ZNRD1 gene was amplified by polymerase chain reaction
(PCR) and sequenced using an ABI Prism 3100 genetic analyzer
(Applied Biosystems). Primers were as follows: for fragment 1,
5′-CGAGACACGGTTCGCAATTA-3′ (forward) and 5′-CAAC-
CCAACCGATCTTGAGT-3′ (reverse); for fragment 2, 5′-GGC-
GGTTGTACATTTGGTCT-3’ (forward) and 5′-AATAAGGGAT-
GGGACCAAGG-3′ (reverse); and for fragment 3, 5′-GTTTAGG-
GGAGCCAGTCCTCC-3′ (forward) and 5′-GCCTCATTCCT-
GACTCTACTTTT-3′ (reverse).
The rs3869068 single-nucleotide polymorphism (SNP)
was typed using the TaqMan SNP genotyping assay
(C 26544924_10; Applied Biosystems). HLA-A10 typing of
DNA samples was performed using the HLA-B low-resolution
bulk SSP kit (Olerup) [17].
Cells. HeLa-P4R5-MAGI, TZM-bl, SupT1, and MOLT-
CCR5 cells (AIDS Research and Reference Reagent Program,
US National Institutes of Health) were cultured in Dulbecco
modified Eagle medium (DMEM; Gibco) or Roswell Park Me-
morial Institute (RPMI) 1640 l-glutamine medium (Gibco).
Culture media were supplemented with 10% heat-inactivated
fetal calf serum and antibiotics.
Drugs. Zidovudine was purchased from Sigma-Aldrich.
HIV integrase inhibitor L-731988 was obtained from Merck
[18]. Fusion inhibitor T-20 was synthesized by the Service of
Peptide Synthesis, University of Barcelona (Spain).
Short interfering RNAs. Short interfering RNAs (siRNAs)
targeting ZNRD1 transcript (ZNRD1_1, UCGCUGUGGCU-
UCAACAUCA; ZNRD1_2, CUCGAUGUGGUCAUGAAG-
GAA) and RNF39 transcript (RNF39_1, ACGCCCATTGCA-
GGAGTATTA; RNF39_2, CCGCCGCAGCCTGAGGTCTAA)
were purchased from Qiagen. Nontargeting siRNA control
(siNT) was a commercially available pool from Dharmacon;
siRev/Env (siRNA targeting a viral sequence) has been described
elsewhere [19].
Generation of cell lines stably expressing short hairpin
RNAs. Commercial self-inactivating lentiviral expression vec-
tors (pLKO.1-puro; Sigma) were used to express a short hair-
pin RNA (shRNA) targeting ZNRD1 (shZNRD1, UGUGGC-
UUCAACAUCAACGUU). Briefly, shRNA-expressing lentivi-
ruses were generated by cotransfecting in 293-T cells the pLKO-
1 vector, a helper plasmid (psPAX2), and a vesicular stomatitis
virus G protein–expressing plasmid. Target cells were infected
and shRNA-expressing cells selected as described elsewhere
[19].
Western blot. Cells were harvested, washed, and lysed in
chilled hypotonic buffer (cell lysis buffer; Invitrogen). After
running the samples, membranes were blocked, incubated with
primary antibodies (ZNRD1, 1:1000, Abnova; Actin, 1:2000,
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Figure 1. Polymorphisms analyzed and the linkage disequilibrium (LD) pattern of the ZNRD1 gene. A, Genomic location of genes (green boxes) and
single-nucleotide polymorphisms (SNPs) (arrows) present on chromosome 6p21. In the upper panel, the relative location of SNPs previously associated
with differential human immunodeficiency virus type 1 clinical outcomes is represented [7, 30, 31]. Below, the ZNRD1 gene region screened with
relative positions of analyzed SNPs is shown. SNPs with positive associations after Bonferroni correction are shown in boldface type. B, Linkage
disequilibrium (LD) blocks in the ZNRD1 gene, estimated by means of Haploview software following the 4-gamete-rule algorithm. Haplotypes associated
with long-term nonprogression are indicated in the boxes, along with corresponding corrected P values (nominal P values are shown in parentheses).
Correction for multiple testing was performed by permutation analysis. Colors and values within the LD plot correspond to D′/LOD and D′ LD values,
respectively (D′ is the value of D [Hedridgeos multiallelic D] between the 2 loci; LOD is the log of the likelihood odds ratio, a measure of confidence
in the value of D′).
Santa Cruz Biotechnology) overnight at 4C, and then incu-
bated with a horseradish peroxidase–conjugated antibody [20].
Membranes were revealed with SuperSignal West Pico chemi-
luminescent substrate (Pierce Biotechnology). For RNF39, dif-
ferent commercial antibodies were tested, but none of them
could specifically detect RNF39 protein (data not shown).
Real-time quantitative PCR. Total RNA was obtained us-
ing the RNeasy Mini kit (Qiagen). Relative levels of ZNRD1
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Figure 2. Linkage disequilibrium (LD) pattern of the chromosome 6
region associated with human immunodeficiency virus (HIV) disease pro-
gression.
Table 2. Position, Hardy-Weinberg (HW) Equi-
librium, and Genotype Frequency of the Ana-
lyzed Single-Nucleotide Polymorphisms
The table is available in its entirety in the online
version of Clinical Infectious Diseases
and RNF39 messenger RNAs (mRNAs) were measured by real-
time quantitative PCR (qPCR) and normalized to GUSB mRNA
expression. For human genes, primers and DNA probes were
commercially purchased (assay-on-demand Hs00205908_m1
for ZNRD1, Hs00961882_m1 for RNF39, and Hs99999908_m1
for GUSB; Applied Biosystems).
Viral DNA was extracted using a QiaAmp DNA extraction
kit (QIAmp DNA Blood Mini kit; Qiagen). Quantitative am-
plification of the long terminal repeat [LTR] for viral entry
detection was performed as described elsewhere (primers, 5′-
CAAGCAGCCATGCAAATGTT-3′ [forward] and 5′-TGCACT-
GGATGCAATCTATCC-3′ [reverse]; probe, 5′-AAAGAGACC-
ATCAATGAGGAAGCTGCAGA-3′) [21]. Viral integration was
detected by Alu-LTR preamplification followed by LTR qPCR
[22].
For analyzing HIV-1 transcription, complementary DNA was
used for qPCR of total viral RNA, unspliced RNA, and multiply
spliced RNA, as previously elsewhere [23].
HIV infection and replication. HIV-1 stocks of NL4-3 and
clinical isolate 92UG024 were grown in lymphoid MT-4 cells,
as described elsewhere [24, 25]. The R5 HIV-1 strain BaL was
grown in peripheral blood mononuclear cells stimulated with
phytohemagglutinin and interleukin 12.
HeLa-P4R5-MAGI or TZM-bl cells were seeded in 96-well
plates and infected; 48 h after infection, cells were lysed and
kept frozen until the b-galactosidase assay was performed.
SupT1 cells [25] were infected for 4 h, washed, and resuspended
in RPMI 1640 medium. HIV production was analyzed 3, 5, or
7 days after infection by HIV p24 enzyme-linked immunosor-
bent assay (Innotest HIV p24 antigen; Innogenetics) in culture
supernatants.
b-Galactosidase detection assay. b-Galactosidase activity
in 30 mL of cell extract was quantified by a colorimetric assay,
as described elsewhere [20, 26]. Absorbance was measured at
405–620 nm.
siRNA and plasmid transfection. TZM-bl cells ( )51.5 10
were seeded in 24-well plates. A day later, siRNA or plasmids
were mixed with Lipofectamine 2000 reagent (Invitrogen) in
serum-free medium (Invitrogen) and then added to previously
washed cells. After 4 h, fresh DMEM was added [20, 26]. Plas-
mid DNA was transfected in SupT1 cells by means of Amaxa
Nucleofection technology (Lonza), in accordance with the man-
ufacturer’s recommendations [20, 26]. Then, cells were recov-
ered and seeded in prewarmed 24-well plates. Cell viability and
expression were monitored 2 days after transfection.
RNA from Jurkat cells was extracted using the RNeasy kit
(Qiagen), in accordance with the manufacturer’s instructions.
After reverse transcription with hexamers (Expand RT;
Roche), ZNRD1 was amplified using the following primers,
which introduced, respectively, EcoRI and ClaI (shown in
boldface type): 5′-GAATTCgccaccATGTCTGTCATGGACCT-
CGCCAATAC-3′ and 5′-ATCGATggctcaAGAGTCTTCCTTC-
TCCTGGAACTTG-3′. PCR products were digested with EcoRI
and ClaI, introduced into the pLPCX expression vector (Clon-
tech), and checked by sequencing.
Statistical analysis. The paired Student t test was used for
comparison between groups. Associations for each SNP and
odds ratios were computed using logistic regression, as imple-
mented in SNPassoc R library software [27]. The reference class
was homozygosity for the major allele among controls. Analyses
were done under 4 different genetic models: codominant, dom-
inant, recessive, and additive [28]. The best model was chosen
using the Akaike information criteria. Bonferroni correction
for 13 nonmonomorphic SNPs was used to correct for multiple
comparisons. An additional factor of correction of 2.5 was
applied to account for the use of 4 different genetic models.
Using this criterion, the corrected level of statistical significance
was set to .0023.
Haplotype blocks were estimated using the 4-gamete-rule
algorithm, as implemented in Haploview software [29]. Hap-
lotype comparisons between groups were performed using the
x2 test. Correction for multiple testing was performed by per-
mutation analysis (100,000 random permutations).
RESULTS
Association between polymorphisms in the ZNRD1 gene and
the LTNP phenotype. The genetic location of ZNRD1 is
shown in Figures 1 and 2. To dissect and map the putative
causal gene influencing HIV disease progression on the human
chromosome 6 locus, the entire coding region of ZNRD1 was
resequenced in HIV-positive progressor patients and LTNP pa-
tients. In addition, previously associated polymorphisms—the
rs3869068 SNP, near rs9261174 [7], and HLA-A10 [32]—were
typed.
Fifteen SNPs were found throughout the gene. Twelve SNPs
were informative enough to undergo genetic association anal-
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Table 3. Associations between ZNRD1 Single-Nucleotide Polymorphisms (SNPs) and Long-Term Nonpro-
gression (LTNP)
SNP
Patients, no. (%) Crude
Pa after
adjustment
for HLA-A10LTNP Progression Pa OR (95% CI)
rs9280878 (dominant model) .00074b .03145c
NI/NI 85 (73.9) 82 (92.1) 1.00 (reference)
NI/insG, insG/insG 30 (26.1) 7 (7.9) 0.25 (0.1–0.6)
rs9261268 (additive model) .00049b .00944c
GG 72 (74.3) 80 (92.0) 1.00 (reference)
GA 22 (21.0) 7 (8.0) 0.27 (0.11–0.63)
AA 5 (4.8) 0 (0)
rs1048412 (recessive model) 4.37  105b .00046b
AA, AG 90 (87.4) 89 (100) 1.00 (reference)
GG 13 (12.6) 0 (100) 0.0375 (0.002–0.64)
NOTE. Shown are frequencies, P values, and odds ratios (ORs) for the 3 SNPs with statistically significantly associations
with the LTNP phenotype, before and after adjustment for the presence of HLA-A10. All data are adjusted for sex. CI, confidence
interval; insG, G insertion; NI, no insertion.
a P value for SNP in best-fitting genetic model.
b Statistically significant after Bonferroni correction ( ).P ! .0023
c Statistically significant by only.P ! .05
ysis, together with rs3869068 (Figure 1A). All SNPs were in
Hardy-Weinberg equilibrium and had a successful genotyping
frequency of 190% (Table 2).
Three of the SNPs—rs9280878 ( , dominant mod-Pp .00074
el), rs9261268 ( , additive model), and rs1048412Pp .00049
( , recessive model)—were found to be statisti-5Pp 4.37 10
cally significantly associated with the LTNP phenotype after Bon-
ferroni correction (defined as ) (Table 3). The rs3869068P ! .0023
SNP showed a positive nominal P value (recessive ).Pp .0029
To complete our analysis, HLA-A10 genotypes were added to the
model. Despite the high linkage disequilibrium of the genomic
region, the rs1048412 SNP still remained statistically significantly
associated with disease progression ( ) (Table 1),Pp .00046
whereas HLA-A10 was not associated with progression after Bon-
ferroni correction ( ).Pp .00938
The linkage disequilibrium structure of the ZNRD1 genomic
region was determined, with 2 haplotype blocks determined
(Figure 1B). The larger block contained 6 SNPs and included
3 ZNRD1 exons. The second block contained 3 SNPs and in-
cluded the last exon of the ZNRD1 gene (Figure 1B). Positive
associations, with analysis performed using all possible marker
haplotypes contained in the blocks, were found and involved
a haplotype in each of the blocks (Figure 1B) [29].
Inhibition of HIV-1 replication due to down-regulation of
ZNRD1 expression but not of RNF39 expression. The effect
of ZNRD1 and RNF39 on HIV-1 infection was evaluated using
RNA interference. HeLa-P4R5-MAGI cells were transiently
transfected with siRNAs targeting ZNRD1 (siZNRD1_1 and
siZNRD1_2) and RNF39 (siRNF39_1 and siRNF39_2), and
their effect was assessed by real-time qPCR; siZNRD1_1 and
RNF39_2 were the sequences that achieved the best silencing
(Figure 3A). Western blot analysis of ZNRD1 protein levels
showed a correlation with mRNA levels (Figure 3B).
siRNA-transfected HeLa-P4R5-MAGI cells were infected
with the X4-tropic NL4-3 strain. Transfection with siZNRD1_1
inhibited HIV-1 replication (Figure 3C), compared with that
in mock-transfected or siNT-transfected cells, whereas neither
of the siRNAs targeting RNF39 was able to inhibit replication.
siZNRD1_2, which produced only a mild reduction in ZNRD1
expression levels, did not statistically significantly inhibit HIV-
1 replication (Figure 3C).
The role played by ZNRD1 in HIV-1 infection was confirmed
by infecting siRNA-treated HeLa-P4R5-MAGI cells with the
R5-tropic laboratory-adapted strain BaL and the clinical isolate
UG024 (Figure 3D). ZNRD1 silencing impaired viral replication
of BaL and UG024 to an extent similar to that of NL4-3 (mean
inhibition  standard deviation [SD], for NL4-63% 15%
3, for BaL, and for UG024) (Figure70% 15% 72% 6%
3D).
TZM-bl cells stably expressing a shRNA targeting ZNRD1
(TZMshZNRD1) or a nontargeting control shRNA (TZMshCTRL)
were generated. Specific down-regulation of ZNRD1 gene ex-
pression was confirmed at the mRNA (Figure 3E) and protein
(Figure 4) levels. Acute infection of TZMshZNRD1 cells inhibited
HIV-1 NL4-3 replication (mean decrease  SD, 60%
), compared with that in wild-type TZM-bl cells or0.1%
TZMshCTRL cells (mean  SD, ) (Figure 3F). No101% 3%
changes were observed in cell viability or in CD4 receptor and
HIV coreceptor cell-surface expression (data not shown).
Figure 3. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication due to ZNRD1 RNA interference–mediated silencing in HeLa-derived
cell lines. A, RNA interference–mediated inhibition of ZNRD1 and RNF39 transcript expression. Relative messenger RNA (mRNA) quantification of
ZNRD1 and RNF39 in HeLa-P4R5-MAGI cells transfected with different short interfering RNAs (siRNAs) targeting these cellular transcripts is shown.
A nontargeting siRNA (siNT) and a siRNA targeting a viral sequence (siRev/Env) were used as controls. Values were normalized to those of mock-
transfected cells. Means  standard deviations (SDs) for 3 independent experiments are represented. B, Western blot of ZNRD1 in HeLa-P4R5-MAGI
cells transfected with siRNA targeting ZNRD1 transcript. C, Inhibition of HIV-1 replication in siRNA targeting ZNRD1, but not RNF39, mRNA. The
percentage of HIV-1 NL4-3 replication compared with mock control is shown. Means  SDs for at least 3 independent experiments are represented.
D, Inhibition of replication of R5 and X4 HIV-1 strains by siZNRD1-treated cells. The percentage of viral replication for 3 different viruses compared
with the mock control is shown. Means  SDs for 3 independent experiments are represented. E, ZNRD1 mRNA stable down-regulation by short
hairpin RNA (shRNA) in TZM-bl cells. Relative ZNRD1 mRNA quantification in wild-type TZM-bl cells (TZMwt), cells harboring a nontargeting control
shRNA (TZMshCTRL), and stably silenced ZNRD1 cells (TZMshZNRD1) is shown. Values were normalized to those of wild-type cells. Means  SDs for 3
independent experiments are represented. F, Inhibition of HIV-1 replication in TZMshZNRD1 cells. The percentage of HIV-1 NL4-3 replication compared
with that in wild-type cells is shown. Means  SDs for at least 3 independent experiments are represented. bgal, b-galactosidase; ND, no drug.
* ; ** ; *** .P ! .05 P ! .005 P ! .0005
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Figure 4. Inhibition of ZNRD1 protein expression in TZM-bl cells.
Figure 5. Impairment of human immunodeficiency virus type 1 (HIV-1) replication in lymphoid cells due to ZNRD1 inhibition by short hairpin RNA
(shRNA). A, ZNRD1 messenger RNA (mRNA) stable down-regulation by shRNA in SupT1 cells. Relative ZNRD1 mRNA quantification in wild-type SupT1
cells (SupT1wt), cells harboring a control shRNA targeting luciferase (SupT1shLUC), and stably silenced ZNRD1 cells (SupT1shZNRD1) is shown. Values were
normalized to those of wild-type cells. Means  standard deviations (SDs) for 3 independent experiments are represented. ** . B, GrowthP ! .005
kinetics of SupT1 cells containing shRNAs. Cell growth during 5 days was measured as the number of cells per milliliter. Means  SDs for 2 different
measurements are represented. C, Inhibition of HIV-1 replication in SupT1shZNRD1 cells. Percentage of HIV-1 NL4-3 replication compared with wild-type
cells is shown. Means  SDs for at least 3 independent experiments are represented. ND; no drug. ** ; *** . D, Time course ofP ! .005 P ! .0005
p24 production in SupT1 cells. p24 production in cell supernatants was measured 3, 5, and 7 days after infection. Inhibition of HIV-1 NL4-3 replication
was maintained during the course of infection. A representative experiment is shown. CAp24, HIV-1 capsid 24 antigen.
Effect of ZNRD1 on HIV-1 replication in lymphoid cells.
A SupT1 lymphoid cell line stably down-regulating ZNRD1
expression (SupT1shZNRD1) or harboring a shRNA targeting the
luciferase gene (SupT1shLUC) were generated (Figure 5A).
Changes in the expression of CD4, CXCR4, or CD8 were not
detected (data not shown), nor were any detrimental effects on
cell viability or proliferation observed in a growth kinetics curve
(Figure 5B).
Acute infection of the engineered shRNA-expressing SupT1
cells with NL4-3 showed that ZNRD1 down-regulation inhib-
ited HIV-1 replication (mean inhibition  SD, ),64% 19%
compared with that in wild-type or control cells (mean inhi-
bition  SD, ) (Figure 5C and 5D).5% 20%
Restoration of HIV replication due to complementation of
wild-type ZNRD1 expression in shZNRD1 cells. SupT1 and
TZM-bl cell lines stably down-regulating ZNRD1 expression
were transfected with a wild-type ZNRD1 expression plasmid
(pZNRD1) or, alternatively, with a green fluorescent protein
expression plasmid as a control. Recovery or overexpression of
wild-type ZNRD1 was measured by real-time qPCR, which
showed an increase in ZNRD1 expression in pZNRD1-trans-
fected cells, compared with that in mock-transfected cells (Fig-
ure 6). Overexpression of the wild-type protein completely re-
stored ZNRD1 mRNA expression levels in SupT1 cells, in which
shZNRD1 inhibition was more modest, but only partially re-
stored them in TZM-bl cells, in which inhibition was more
potent (Figure 6). Acute infection with NL4-3 restored HIV-1
replication levels in both TZMshZNRD1 and SupT1shZNRD1 cells
transfected with the ZNRD1 expression plasmid (mean  SD,
for TZMshZNRD1 and for SupT1shZNRD1),51% 4% 150% 40%
compared with those in mock-transfected cells (mean  SD,
for TZMshZNRD1 and for SupT1shZNRD1)13% 10% 42% 3%
or cells transfected with the control plasmid (mean  SD,
for TZMshZNRD1 and for SupT1shZNRD1)8% 1% 29% 5%
(Figure 7).
ZNRD1: Cofactor of HIV Replication • CID 2010:50 (1 April) • 1029
Figure 6. Restoration of ZNRD1 expression in TZM and SupT1 cell
lines.
Figure 7. Recovery of human immunodeficiency virus type 1 (HIV-1) replication due to restoration of ZNRD1 expression in TZM-blshZNRD1 and SupT1shZNRD1
cell lines. The percentage of HIV-1 NL-43 replication in the different TZM-bl cells (A) or SupT1 cells (B) transfected with a green fluorescent protein–
expressing control plasmid (pGFP) or a plasmid expressing wild-type ZNRD1 (pZNRD1) is shown. HIV-1 replication was recovered in shZNRD1 cells
when ZNRD1 expression was restored. Means  standard deviations for at least 3 independent experiments are represented. bgal, b-galactosidase;
CAp24, HIV-1 capsid 24 antigen. * ; ** ; *** .P ! .05 P ! .005 P ! .0005
Effect of ZNRD1 on viral transcription from the LTR
promoter. MOLT-CCR5 cells persistently infected with HIV-
1 strain NL4-3 were cocultured together with HeLa-P4R5-
MAGI cells transfected with siZNRD1_1 or siNT (nontargeting
siRNA control). Fusion was monitored by intracellular b-ga-
lactosidase staining of overnight cocultures. ZNRD1 depletion
did not alter HIV-1 envelope–mediated fusion (Figure 8).
Proviral DNA was measured 8 h after infection in TZMshZNRD1
and SupT1shZNRD1 cells together with their respective control
and parental cell lines. No differences were observed between
shZNRD1 and control cells (Figure 9A), indicating that ZNRD1
down-regulation did not affect viral entry or reverse transcrip-
tion [21]. Viral integration at 24 h was quantified by Alu-LTR
PCR followed by proviral DNA PCR [22]. Again, ZNRD1 in-
hibition did not alter HIV-1 proviral DNA integration (Figure
9A). Similar results were obtained with HeLa-P4R5-MAGI cells
transfected with siZNRD1 (data not shown).
Viral transcription was measured 3 days after infection by
real-time qPCR of different viral mRNA species (gag, nef, and
multiply spliced tat/rev/nef). In all cases, ZNRD1 silencing led
to a statistically significant decrease in the relative amount of
viral mRNA, compared with that in control or wild-type cells
(Figure 9B). Taken together, these results pointed to viral tran-
scription as the step inhibited by ZNRD1 silencing.
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Figure 8. No inhibition of human immunodeficiency virus (HIV) fusion
due to ZNRD1 silencing.
Figure 9. Inhibition of human immunodeficiency virus type 1 (HIV-1) transcription due to down-regulation of ZNRD1 expression. A, HIV-1 proviral
DNA, measured by quantitative polymerase chain reaction (qPCR), in TZM-bl and SupT1 cells at 8 (black bars) and 24 (white bars) h after infection,
in this case preceded by a first round of Alu–long terminal repeat PCR. The number of HIV-1 proviral copies per cell was obtained using a standard
curve and quantification of the cellular gene RNAseP. Values are expressed as percentages compared with those in wild-type cells. Means  standard
deviations (SDs) for 3 independent experiments are represented. AZT, zidovudine. B, Relative ratios of different HIV-1 transcripts (nef, gag, and multiply
spliced messenger RNAs) measured by real-time qPCR and normalized to b-actin in TZM-bl cells 3 days after infection. Means  SDs for 3 replicates
of a representative experiment are represented. * ; ** ; *** .P ! .05 P ! .005 P ! .0005
DISCUSSION
The results of different genomewide screens have been pub-
lished, which have aimed to describe genes that confer different
susceptibilities to AIDS or cellular genes that are functionally
required for viral replication [6–8, 10, 30, 33]. Strikingly, little
overlap can be identified between them [4], therefore making
essential the replication of genetic data in independent cohorts
and further functional validation and characterization of se-
lected genes [34].
Here, taking as a starting point the results of genomewide
analyses [6, 7], we validated, clarified, and functionally char-
acterized the implication of ZNRD1 in HIV-1 replication. Using
RNA interference, we clearly demonstrated that ZNRD1 de-
pletion, but not RNF39 depletion, impaired HIV replication.
Importantly, ZNRD1 down-regulation hampered HIV repli-
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cation in lymphoid cell lines without altering cell viability or
proliferation, expanding its relevance to cells that are natural
HIV targets. Moreover, we narrowed the molecular step at
which ZNRD1 affects viral replication to the transcriptional
level. Importantly, we found that genetic polymorphisms lo-
cated in the ZNRD1 gene were statistically significantly asso-
ciated with the LTNP phenotype independently of HLA-A ef-
fects, thus providing further indication that the ZNRD1 gene
is a novel cofactor that affects the course of HIV infection both
in vitro and in vivo.
Every step of the HIV life cycle depends on the cellular
machinery [35]. For ZNRD1, we have narrowed down its mode
of action to viral transcription from the LTR promoter, dis-
carding any effect on early events of virus replication. In agree-
ment with our data, Brass et al [6] have suggested that ZNRD1
could act before Gag translation. Additional work will be
needed to clearly understand the mode of action of ZNRD1 in
HIV-1 infection. An important element to elucidate would be
the apparent partial effect of transient and stable RNA inter-
ference of ZNRD1. In addition, the potency of RNA-dependent
knockdown appeared to correlate with the potency of inhibition
of virus replication, but total knockout could not be achieved.
These results, together with the observation that complemen-
tation of ZNRD1 expression in wild-type cells did not increase
virus replication, suggest that a low level of expression of
ZNRD1 may be sufficient to allow replication and that complete
gene knockout should be required to abolish virus production.
Human susceptibility to viral infection can be seen as the
final result of a dynamic interplay between the genetic makeup
of the individual host and the pathogen, with environmental
influences adding another layer of complexity. In the middle
of such an intricate picture, however, several genetic polymor-
phisms have been described that clearly influence the outcome
of HIV infection, specially in the HLA region, where ZNRD1
is located [7, 31, 36, 37]. Genetic complexity and the high
linkage disequilibrium of the region challenges the effect of
ZNRD1 on HIV disease progression [32, 37]. Unlike the find-
ings of these studies, our data point to a role for the ZNRD1
gene in HIV disease progression independent of the HLA-A10
allele, a factor proposed to be responsible for much of the effect
of ZNRD1 [32]. Polymorphisms in the ZNRD1 gene remained
statistically significantly associated with the LTNP phenotype
when HLA-A10 was introduced as a covariable in the analysis.
In addition, the effect of HLA-A10 was not statistically signif-
icantly associated with progression, suggesting a more discrete
effect (if any) and an independent role for ZNRD1, in accor-
dance with the findings of other association studies [7, 30, 31,
37]. Although the earlier studies were based on the complex
spatial structure and linkage disequilibrium pattern of a rela-
tively large region, we took a more focused approach on in-
dividual polymorphisms around the ZNRD1 gene, because of
its demonstrated effect on HIV-1 replication in cell culture.
Observations of determinants for host control of infection
based on SNPs need to be replicated in relevant populations,
followed by deeper genomic and functional analyses of the
associated region to verify putative causal variants. Identifica-
tion of polymorphisms in relevant genes might be the key to
unraveling the basis of the pathogenesis of HIV-1 disease. We
did not identify any point mutations or polymorphisms with
clear functional implications, either at the mRNA or protein
level. However, the rs9280878 SNP has been predicted to create
a novel splice site that leads to a different mRNA isoform
without altering the gene coding sequence. Moreover, the SNP
with the lowest P value (rs1048412) is located in the 3′ un-
translated region of the ZNRD1 gene, a region putatively in-
volved in posttranscriptional mRNA regulation by, for example,
microRNAs [38]. Thus, the possibility that the identified SNPs
might have an effect on mRNA properties could not be dis-
carded [39]. Polymorphisms or haplotypes that affect such fea-
tures as mRNA biogenesis, transport, or stability may have an
effect on ZNRD1 and lead to altered expression levels, with
effects on HIV replication resembling the results obtained in
vitro. Future work will shed light on the putative regulatory
mechanisms (if any) that underlie the identified SNPs.
A key therapeutic strategy for treating HIV-positive patients
has been to simultaneously target multiple virus-encoded pro-
teins to overcome the emergence of resistance. The identifi-
cation and characterization of cellular cofactors represent a
promising alternative. Indeed, the use of cellular genes as targets
for antiviral drugs is already becoming a reality, as shown for
the CCR5 coreceptor and its antagonist, maraviroc [40, 41].
Targeting multiple host cell gene products would minimize the
acquisition of drug resistance and provide long-lasting blocking
of virus replication.
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